Abstract |
A new transdermal system (BIO TSD) containing the beta-adrenergic blocker mepindolol was assessed in a placebo controlled clinical trial in 12 patients with coronary heart disease. On therapy, the number of anginal attacks and the consumption of oral nitroglycerin ( glyceryl trinitrate) were reduced significantly. During ergometer exercise the exercise tolerance was improved and the ischemic ST-segment depression was reduced significantly. Holter monitoring revealed significant reductions of the number of manifest and silent episodes and the total duration of ischemia. No relevant side effects were observed.
|
Authors | J Bonelli, F Gazo, R K Liedtke |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 39
Issue 11A
Pg. 1515-7
(Nov 1989)
ISSN: 0004-4172 [Print] Germany |
Vernacular Title | Antiischämische Wirkung des transdermal applizierten beta-Rezeptorenblockers Mepindolol bei Patienten mit stabiler Angina pectoris. |
PMID | 2576203
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Adrenergic beta-Antagonists
- mepindolol
- Pindolol
- Nitroglycerin
|
Topics |
- Administration, Cutaneous
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Aged
- Angina Pectoris
(drug therapy, physiopathology)
- Coronary Disease
(drug therapy, physiopathology)
- Electrocardiography
- Female
- Heart Rate
(drug effects)
- Humans
- Male
- Middle Aged
- Nitroglycerin
(administration & dosage, therapeutic use)
- Pindolol
(administration & dosage, analogs & derivatives, therapeutic use)
|